445 related articles for article (PubMed ID: 20501833)
1. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
3. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
Mitchell JB; Choudhuri R; Fabre K; Sowers AL; Citrin D; Zabludoff SD; Cook JA
Clin Cancer Res; 2010 Apr; 16(7):2076-84. PubMed ID: 20233881
[TBL] [Abstract][Full Text] [Related]
5. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
Engelke CG; Parsels LA; Qian Y; Zhang Q; Karnak D; Robertson JR; Tanska DM; Wei D; Davis MA; Parsels JD; Zhao L; Greenson JK; Lawrence TS; Maybaum J; Morgan MA
Clin Cancer Res; 2013 Aug; 19(16):4412-21. PubMed ID: 23804422
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
8. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Zabludoff SD; Deng C; Grondine MR; Sheehy AM; Ashwell S; Caleb BL; Green S; Haye HR; Horn CL; Janetka JW; Liu D; Mouchet E; Ready S; Rosenthal JL; Queva C; Schwartz GK; Taylor KJ; Tse AN; Walker GE; White AM
Mol Cancer Ther; 2008 Sep; 7(9):2955-66. PubMed ID: 18790776
[TBL] [Abstract][Full Text] [Related]
9. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
[TBL] [Abstract][Full Text] [Related]
10. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
Venkatesha VA; Parsels LA; Parsels JD; Zhao L; Zabludoff SD; Simeone DM; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2012 Jun; 14(6):519-25. PubMed ID: 22787433
[TBL] [Abstract][Full Text] [Related]
13. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Parsels LA; Tanska DM; Parsels JD; Zabludoff SD; Cuneo KC; Lawrence TS; Maybaum J; Morgan MA
Cell Cycle; 2016; 15(5):730-9. PubMed ID: 26890478
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
[TBL] [Abstract][Full Text] [Related]
17. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
Fokas E; Prevo R; Pollard JR; Reaper PM; Charlton PA; Cornelissen B; Vallis KA; Hammond EM; Olcina MM; Gillies McKenna W; Muschel RJ; Brunner TB
Cell Death Dis; 2012 Dec; 3(12):e441. PubMed ID: 23222511
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
Liu B; Chen W; Li H; Li F; Jin X; Li Q
Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
Xu H; Cheung IY; Wei XX; Tran H; Gao X; Cheung NK
Int J Cancer; 2011 Oct; 129(8):1953-62. PubMed ID: 21154747
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
